Consumer Health Cancer / Immunology

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

 The agreement aims to supply ImmunityBio with Bacillus Calmette-Guerin (BCG), a critical component in cancer treatment. Under the collaboration, the ...

 May 06, 2024 | News

ImmunityBio and Serum Institute of India Secure Global BCG Supply Agreement for Cancer Treatment

Collaboration will result in BCG manufacture at large scale for use in combination with ANKTIVA®, ImmunityBio’s recently approved treatme...

 May 03, 2024 | News

Aubex Therapeutics Launches, Targeting Cancer with Novel TME Compounds

Aubex Therapeutics Inc., a pioneering biotechnology firm, announced its official launch, heralding a new era in the battle against cancer. Under the guidan...

 May 02, 2024 | News

Jacobio Pharma Reports Promising Phase II Results for Glecirasib in Lung Cancer at ASCO

Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at th...

 May 01, 2024 | News

Infinitopes Raises £12.8M to Expand Precision Immunomics™ for Five Additional Cancers

      - Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen disco...

 May 01, 2024 | News

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

 April 29, 2024 | News

Hyundai Bioscience Targets p53 Gene Mutations with Novel Niclosamide-Based Cancer Therapy

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatm...

 April 26, 2024 | News

Dizal to Present New Data on Sunvozertinib for Lung Cancer at ASCO 2024

Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases...

 April 25, 2024 | News

Hanmi Pharmaceutical Partners with MSD to Advance Immuno-Oncology Drug BH3120 in New Clinical Trial

Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesit...

 April 24, 2024 | News

OSR Holdings and SillaJen Forge Strategic Partnership to Enhance Immuno-Oncology Drug Development

OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech ...

 April 23, 2024 | News

Hyundai Bioscience Launches Clinical Trials for Innovative Niclosamide-Based Cancer Drug

Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative...

 April 23, 2024 | News

GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...

 April 22, 2024 | News

Serum Institute of India and Univercells Unite to Make Personalized Cancer Treatments Widely Available

 Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator,...

 April 12, 2024 | News

Transcenta and Agilent Collaborate on Companion Diagnostic for Advanced Gastric Cancer Trial

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

 April 09, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in